Real-world evidence on infection risks from multiple sclerosis treatments remains limited, with inconsistent findings ...

Rising metabolic score for insulin resistance (METS-IR) levels strongly correlate with major cardiovascular events (MACE) and ...

Panelists discuss the challenges of biologic access in hidradenitis suppurativa due to utilization management policies like ...

Patients with chronic lymphocytic leukemia (CLL) had significantly lower monocyte-to-lymphocyte ratio values compared with ...

In advanced non–small cell lung cancer (NSCLC), discontinuing immunotherapy after 2 years can maintain durable responses ...

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.

Making treatment for non–small cell lung cancer (NSCLC) accessible to a wide range of the population can help to improve ...

A qualitative study found strong support for primary care provider–nephrologist comanagement of chronic kidney disease (CKD), ...

The humanized IgG4 monoclonal antibody was first approved for myasthenia gravis in the US in 2023, with approvals in Japan ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Panelists discuss the anticipated 2026 updates to the American Academy of Dermatology guidelines for hidradenitis suppurativa, highlighting efforts to unify treatment protocols, support biologic ...

James Chalmers, MBChB, PhD, highlights the reassuring safety and tolerability profile of brensocatib in patients with non–cystic fibrosis bronchiectasis.